Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101


MCAM is a novel metastasis marker and regulates spreading, apoptosis and invasion of ovarian cancer cells.

Wu Z, Wu Z, Li J, Yang X, Wang Y, Yu Y, Ye J, Xu C, Qin W, Zhang Z.

Tumour Biol. 2012 Oct;33(5):1619-28. doi: 10.1007/s13277-012-0417-0. Epub 2012 May 19.


ETV5 transcription factor is overexpressed in ovarian cancer and regulates cell adhesion in ovarian cancer cells.

Llauradó M, Abal M, Castellví J, Cabrera S, Gil-Moreno A, Pérez-Benavente A, Colás E, Doll A, Dolcet X, Matias-Guiu X, Vazquez-Levin M, Reventós J, Ruiz A.

Int J Cancer. 2012 Apr 1;130(7):1532-43. doi: 10.1002/ijc.26148. Epub 2011 Aug 12.


Targeting the ROR1 and ROR2 receptors in epithelial ovarian cancer inhibits cell migration and invasion.

Henry C, Llamosas E, Knipprath-Meszaros A, Schoetzau A, Obermann E, Fuenfschilling M, Caduff R, Fink D, Hacker N, Ward R, Heinzelmann-Schwarz V, Ford C.

Oncotarget. 2015 Nov 24;6(37):40310-26. doi: 10.18632/oncotarget.5643.


Epithelial protein lost in neoplasm-α (EPLIN-α) is a potential prognostic marker for the progression of epithelial ovarian cancer.

Liu R, Martin TA, Jordan NJ, Ruge F, Ye L, Jiang WG.

Int J Oncol. 2016 Jun;48(6):2488-96. doi: 10.3892/ijo.2016.3462. Epub 2016 Mar 29.


PDCD6 is an independent predictor of progression free survival in epithelial ovarian cancer.

Su D, Xu H, Feng J, Gao Y, Gu L, Ying L, Katsaros D, Yu H, Xu S, Qi M.

J Transl Med. 2012 Feb 27;10:31. doi: 10.1186/1479-5876-10-31.


Human epithelial-type ovarian tumour marker beta-2-microglobulin is regulated by the TGF-β signaling pathway.

Sun W, Gui L, Zuo X, Zhang L, Zhou D, Duan X, Ren W, Xu G.

J Transl Med. 2016 Mar 16;14:75. doi: 10.1186/s12967-016-0832-x.


Overexpression of long non-coding RNA HOTAIR predicts poor patient prognosis and promotes tumor metastasis in epithelial ovarian cancer.

Qiu JJ, Lin YY, Ye LC, Ding JX, Feng WW, Jin HY, Zhang Y, Li Q, Hua KQ.

Gynecol Oncol. 2014 Jul;134(1):121-8. doi: 10.1016/j.ygyno.2014.03.556. Epub 2014 Mar 22.


The role of RhoC in ovarian epithelial carcinoma: a marker for carcinogenesis, progression, prognosis, and target therapy.

Zhao Y, Zheng HC, Chen S, Gou WF, Xiao LJ, Niu ZF.

Gynecol Oncol. 2013 Sep;130(3):570-8. doi: 10.1016/j.ygyno.2013.06.004. Epub 2013 Jun 10.


The membrane protein melanoma cell adhesion molecule (MCAM) is a novel tumor marker that stimulates tumorigenesis in hepatocellular carcinoma.

Wang J, Tang X, Weng W, Qiao Y, Lin J, Liu W, Liu R, Ma L, Yu W, Yu Y, Pan Q, Sun F.

Oncogene. 2015 Nov 19;34(47):5781-95. doi: 10.1038/onc.2015.36. Epub 2015 Mar 2.


Thrombomodulin mediates the progression of epithelial ovarian cancer cells.

Chen LM, Wang W, Lee JC, Chiu FH, Wu CT, Tai CJ, Wang CK, Tai CJ, Huang MT, Chang YJ.

Tumour Biol. 2013 Dec;34(6):3743-51. doi: 10.1007/s13277-013-0958-x. Epub 2013 Aug 6.


Downregulation of matrix metalloproteinase 9 by small interfering RNA inhibits the tumor growth of ovarian epithelial carcinoma in vitro and in vivo.

Guo F, Tian J, Cui M, Fang M, Yang L.

Mol Med Rep. 2015 Jul;12(1):753-9. doi: 10.3892/mmr.2015.3425. Epub 2015 Mar 4.


An mDia2/ROCK signaling axis regulates invasive egress from epithelial ovarian cancer spheroids.

Pettee KM, Dvorak KM, Nestor-Kalinoski AL, Eisenmann KM.

PLoS One. 2014 Feb 28;9(2):e90371. doi: 10.1371/journal.pone.0090371. eCollection 2014.


Versican regulates metastasis of epithelial ovarian carcinoma cells and spheroids.

Desjardins M, Xie J, Gurler H, Muralidhar GG, Sacks JD, Burdette JE, Barbolina MV.

J Ovarian Res. 2014 Jun 26;7:70. doi: 10.1186/1757-2215-7-70. eCollection 2014.


HOTAIR is a potential target for the treatment of cisplatin‑resistant ovarian cancer.

Wang Y, Wang H, Song T, Zou Y, Jiang J, Fang L, Li P.

Mol Med Rep. 2015 Aug;12(2):2211-6. doi: 10.3892/mmr.2015.3562. Epub 2015 Mar 27.


Sex-determining region Y-box3 (SOX3) functions as an oncogene in promoting epithelial ovarian cancer by targeting Src kinase.

Yan Q, Wang F, Miao Y, Wu X, Bai M, Xi X, Feng Y.

Tumour Biol. 2016 Sep;37(9):12263-12271. Epub 2016 Jun 1.


Overexpression of CD157 contributes to epithelial ovarian cancer progression by promoting mesenchymal differentiation.

Morone S, Lo-Buono N, Parrotta R, Giacomino A, Nacci G, Brusco A, Larionov A, Ostano P, Mello-Grand M, Chiorino G, Ortolan E, Funaro A.

PLoS One. 2012;7(8):e43649. doi: 10.1371/journal.pone.0043649. Epub 2012 Aug 20.


MicroRNA-145 targets TRIM2 and exerts tumor-suppressing functions in epithelial ovarian cancer.

Chen X, Dong C, Law PT, Chan MT, Su Z, Wang S, Wu WK, Xu H.

Gynecol Oncol. 2015 Dec;139(3):513-9. doi: 10.1016/j.ygyno.2015.10.008. Epub 2015 Oct 16.


CD146 expression is associated with a poor prognosis in human breast tumors and with enhanced motility in breast cancer cell lines.

Zabouo G, Imbert AM, Jacquemier J, Finetti P, Moreau T, Esterni B, Birnbaum D, Bertucci F, Chabannon C.

Breast Cancer Res. 2009;11(1):R1. doi: 10.1186/bcr2215. Epub 2009 Jan 5.

Supplemental Content

Support Center